nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—TNF—acquired immunodeficiency syndrome	0.594	1	CbGaD
Clenbuterol—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0596	0.197	CbGbCtD
Clenbuterol—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.056	0.185	CbGbCtD
Clenbuterol—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.056	0.185	CbGbCtD
Clenbuterol—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0507	0.167	CbGbCtD
Clenbuterol—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0425	0.14	CbGbCtD
Clenbuterol—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0384	0.127	CbGbCtD
Clenbuterol—NGF—nerve—acquired immunodeficiency syndrome	0.012	0.239	CbGeAlD
Clenbuterol—TNF—blood—acquired immunodeficiency syndrome	0.00361	0.0717	CbGeAlD
Clenbuterol—TNF—vagina—acquired immunodeficiency syndrome	0.00335	0.0665	CbGeAlD
Clenbuterol—NGF—blood—acquired immunodeficiency syndrome	0.00334	0.0662	CbGeAlD
Clenbuterol—NGF—spinal cord—acquired immunodeficiency syndrome	0.00321	0.0638	CbGeAlD
Clenbuterol—NGF—lung—acquired immunodeficiency syndrome	0.00292	0.058	CbGeAlD
Clenbuterol—NGF—nervous system—acquired immunodeficiency syndrome	0.00271	0.0537	CbGeAlD
Clenbuterol—NGF—central nervous system—acquired immunodeficiency syndrome	0.00261	0.0517	CbGeAlD
Clenbuterol—TNF—lymph node—acquired immunodeficiency syndrome	0.00217	0.043	CbGeAlD
Clenbuterol—NGF—brain—acquired immunodeficiency syndrome	0.00207	0.0411	CbGeAlD
Clenbuterol—NGF—lymph node—acquired immunodeficiency syndrome	0.002	0.0397	CbGeAlD
Clenbuterol—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00155	0.0308	CbGeAlD
Clenbuterol—ADRB1—lung—acquired immunodeficiency syndrome	0.000761	0.0151	CbGeAlD
Clenbuterol—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000735	0.0146	CbGeAlD
Clenbuterol—ADRB1—nervous system—acquired immunodeficiency syndrome	0.000705	0.014	CbGeAlD
Clenbuterol—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.000679	0.0135	CbGeAlD
Clenbuterol—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000596	0.0118	CbGeAlD
Clenbuterol—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000588	0.0117	CbGeAlD
Clenbuterol—CYP1A2—blood—acquired immunodeficiency syndrome	0.000568	0.0113	CbGeAlD
Clenbuterol—CYP1A1—blood—acquired immunodeficiency syndrome	0.00056	0.0111	CbGeAlD
Clenbuterol—ADRB1—brain—acquired immunodeficiency syndrome	0.000539	0.0107	CbGeAlD
Clenbuterol—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000519	0.0103	CbGeAlD
Clenbuterol—CYP1A2—lung—acquired immunodeficiency syndrome	0.000498	0.00988	CbGeAlD
Clenbuterol—CYP1A1—lung—acquired immunodeficiency syndrome	0.000491	0.00974	CbGeAlD
Clenbuterol—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000455	0.00902	CbGeAlD
Clenbuterol—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000438	0.00869	CbGeAlD
Clenbuterol—TNF—Cytokines and Inflammatory Response—IL2—acquired immunodeficiency syndrome	0.000384	0.00737	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000369	0.00709	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000362	0.00694	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—acquired immunodeficiency syndrome	0.000356	0.00682	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—MBL2—acquired immunodeficiency syndrome	0.000355	0.0068	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000354	0.00679	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.00035	0.00671	CbGpPWpGaD
Clenbuterol—CYP1A1—brain—acquired immunodeficiency syndrome	0.000348	0.0069	CbGeAlD
Clenbuterol—NGF—SHP2 signaling—IL6—acquired immunodeficiency syndrome	0.000336	0.00645	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000336	0.00644	CbGpPWpGaD
Clenbuterol—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000336	0.00666	CbGeAlD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000334	0.00641	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000324	0.00622	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—IFNA1—acquired immunodeficiency syndrome	0.000321	0.00615	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000317	0.00608	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000311	0.00597	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000311	0.00597	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—CCL3—acquired immunodeficiency syndrome	0.000307	0.0059	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.000303	0.00581	CbGpPWpGaD
Clenbuterol—TNF—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000299	0.00574	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000298	0.00573	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000296	0.00568	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	0.000285	0.00546	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000282	0.00541	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000281	0.0054	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000276	0.00529	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000272	0.00522	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00027	0.00517	CbGpPWpGaD
Clenbuterol—TNF—Transcription factor regulation in adipogenesis—IL6—acquired immunodeficiency syndrome	0.000266	0.0051	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.000264	0.00506	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	0.00026	0.00498	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—CCL5—acquired immunodeficiency syndrome	0.000255	0.00489	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000254	0.00488	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000251	0.00481	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—IFNA1—acquired immunodeficiency syndrome	0.00025	0.0048	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.000248	0.00476	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000241	0.00462	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000238	0.00457	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.000235	0.0045	CbGpPWpGaD
Clenbuterol—TNF—IL27-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000233	0.00446	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000232	0.00444	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000228	0.00438	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000226	0.00434	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—IL6—acquired immunodeficiency syndrome	0.000226	0.00433	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.00022	0.00421	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000219	0.00421	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000214	0.00411	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000211	0.00406	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	0.000211	0.00406	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000207	0.00398	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000206	0.00396	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—CCL5—acquired immunodeficiency syndrome	0.000199	0.00382	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000198	0.0038	CbGpPWpGaD
Clenbuterol—TNF—amb2 Integrin signaling—IL6—acquired immunodeficiency syndrome	0.000197	0.00378	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000194	0.00372	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000194	0.00372	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000194	0.00372	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000189	0.00362	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	0.000188	0.0036	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000188	0.0036	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000184	0.00353	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000183	0.00351	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000181	0.00347	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000178	0.00341	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000175	0.00337	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000174	0.00333	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000168	0.00322	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000167	0.0032	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000165	0.00316	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000165	0.00316	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000163	0.00313	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.000163	0.00312	CbGpPWpGaD
Clenbuterol—TNF—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000159	0.00304	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000157	0.00301	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000156	0.003	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000155	0.00298	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000155	0.00297	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000152	0.00292	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000151	0.0029	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000149	0.00286	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000148	0.00283	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000148	0.00283	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000148	0.00283	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000148	0.00283	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000144	0.00277	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000143	0.00274	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000141	0.00271	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000141	0.0027	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00014	0.00268	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000138	0.00265	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000138	0.00264	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	0.000136	0.0026	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000135	0.0026	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000134	0.00258	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000133	0.00255	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000133	0.00255	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000133	0.00254	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000132	0.00252	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000131	0.0025	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000122	0.00235	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	0.000122	0.00234	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00012	0.0023	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000118	0.00226	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000115	0.00221	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000115	0.00221	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000113	0.00216	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00216	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000112	0.00216	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000111	0.00212	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.00011	0.00212	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000103	0.00198	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000102	0.00195	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000101	0.00194	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000101	0.00194	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.0001	0.00192	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.0001	0.00192	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	9.88e-05	0.00189	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.38e-05	0.0018	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.33e-05	0.00179	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.21e-05	0.00177	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.21e-05	0.00177	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.13e-05	0.00175	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.01e-05	0.00173	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.92e-05	0.00171	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.88e-05	0.0017	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	8.78e-05	0.00168	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	8.77e-05	0.00168	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.77e-05	0.00168	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.77e-05	0.00168	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.76e-05	0.00168	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.66e-05	0.00166	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.66e-05	0.00166	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.58e-05	0.00165	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.58e-05	0.00165	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.57e-05	0.00164	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.57e-05	0.00164	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.53e-05	0.00164	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.53e-05	0.00164	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	8.47e-05	0.00162	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.38e-05	0.00161	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.35e-05	0.0016	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.35e-05	0.0016	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.35e-05	0.0016	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.17e-05	0.00157	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.07e-05	0.00155	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.89e-05	0.00151	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.8e-05	0.0015	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.75e-05	0.00149	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.72e-05	0.00148	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.71e-05	0.00148	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.58e-05	0.00145	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.58e-05	0.00145	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.58e-05	0.00145	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.06e-05	0.00135	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	6.94e-05	0.00133	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.67e-05	0.00128	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.59e-05	0.00126	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.53e-05	0.00125	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.49e-05	0.00124	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—IL6—acquired immunodeficiency syndrome	6.42e-05	0.00123	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	6.39e-05	0.00123	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	6.39e-05	0.00123	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.35e-05	0.00122	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.26e-05	0.0012	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	6.09e-05	0.00117	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.01e-05	0.00115	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.93e-05	0.00114	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.88e-05	0.00113	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	5.8e-05	0.00111	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.77e-05	0.00111	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.72e-05	0.0011	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.68e-05	0.00109	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.55e-05	0.00106	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.29e-05	0.00102	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.27e-05	0.00101	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.27e-05	0.00101	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.2e-05	0.000997	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.18e-05	0.000993	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.16e-05	0.000989	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.06e-05	0.000971	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.06e-05	0.000971	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.96e-05	0.000951	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.96e-05	0.000951	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.95e-05	0.00095	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.95e-05	0.00095	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.93e-05	0.000945	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.85e-05	0.00093	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.85e-05	0.00093	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.79e-05	0.000918	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.76e-05	0.000914	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.68e-05	0.000898	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.58e-05	0.000878	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.5e-05	0.000863	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.5e-05	0.000863	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.48e-05	0.000859	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.48e-05	0.000859	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.48e-05	0.000859	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.4e-05	0.000845	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.4e-05	0.000845	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.77e-05	0.000723	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.71e-05	0.000712	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	3.7e-05	0.000709	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.69e-05	0.000707	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.63e-05	0.000697	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.43e-05	0.000658	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.000657	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.41e-05	0.000654	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.4e-05	0.000652	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.000647	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.36e-05	0.000644	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.35e-05	0.000642	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.32e-05	0.000637	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.31e-05	0.000634	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.3e-05	0.000633	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.14e-05	0.000603	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.13e-05	0.0006	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.000592	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.07e-05	0.000589	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.06e-05	0.000587	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.02e-05	0.000579	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3e-05	0.000576	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.83e-05	0.000542	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.77e-05	0.000531	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.66e-05	0.00051	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.66e-05	0.00051	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.6e-05	0.000499	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.6e-05	0.000499	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.27e-05	0.000435	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.21e-05	0.000423	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.02e-05	0.000388	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.02e-05	0.000387	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.99e-05	0.000382	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.98e-05	0.00038	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.96e-05	0.000376	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.95e-05	0.000374	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.92e-05	0.000368	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.82e-05	0.00035	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.78e-05	0.000342	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000342	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.77e-05	0.00034	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.77e-05	0.000339	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.74e-05	0.000334	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.45e-05	0.000278	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000202	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000201	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.04e-05	0.0002	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.03e-05	0.000198	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000197	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	1.01e-05	0.000194	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	6.44e-06	0.000124	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.19e-06	0.000119	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.05e-06	0.000116	CbGpPWpGaD
